CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性弥漫大 B 细胞淋巴瘤的新型生物疗法：CAR-T 并非唯一答案
英文原题：Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
查看英文原题
Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
一线治疗后仍难治或复发的弥漫大B细胞淋巴瘤患者，采用传统疗法预后较差。近年来，研究者为引入广泛的新型靶向疗法付出了大量努力，其中最值得关注的是CAR-T 细胞疗法。由于并发症风险相对较高且治疗可及性有限，并非所有患者都适合CAR-T 治疗。本文讨论近年推出的有前景新型生物疗法，并综述该领域正在开展的临床试验。
展开英文摘要原文
Patients with diffuse large B-cell lymphoma who have refractory or relapsed disease following first line treatment have a poor prognosis when treated with conventional therapies. Significant efforts have been made in recent years to bring a broad spectrum of novel targeted therapies, the most noteworthy of which is chimeric antigen receptor T-cell therapy (CAR-T). Not all patients are eligible for CAR-T given the relatively high risk of complications and limited availability.
Here we discuss promising novel biologic therapies that have been introduced in the last few years and go over ongoing clinical trials in the field.
论文信息
- 作者
- Paillassa J、Safa F
- 单位
- Service des maladies du sang, Centre Hospitalier Universitaire D'Angers France.France
- 文献类型
- 综述
- 期刊
- Leukemia research reports2022
- 原文标识
- PubMed 35024331 · DOI 10.1016/j.lrr.2021.100282
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →